Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
NCT03510715Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of alirocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Sanofi. Started Aug 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03510715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510715.